Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference

R. Hassan, R. Alexander, K. Antman, P. Boffetta, A. Churg, D. Coit, P. Hausner, R. Kennedy, H. Kindler, M. Metintas, L. Mutti, M. Onda, H. Pass, A. Premkumar, V. Roggli, D. Sterman, P. Sugarbaker, R. Taub, C. Verschraegen

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations

Abstract

Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.

Original languageEnglish
Pages (from-to)1615-1619
Number of pages5
JournalAnnals of Oncology
Volume17
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Keywords

  • Cancer
  • Mesothelioma
  • Peritoneal

Fingerprint

Dive into the research topics of 'Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference'. Together they form a unique fingerprint.

Cite this